Tumor Microenvironment and Immune Suppression

Similar documents
Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

Darwinian selection and Newtonian physics wrapped up in systems biology

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Tumor Associated Macrophages as a Novel Target for Cancer Therapy

Improving cancer immunotherapy by targeting tumorinduced immune suppression

Immunological Tolerance

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

Cell-mediated Immunity

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Ανοσολογικοί μηχανισμοί στην ανοσοθεραπεία καρκίνου

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

Cancer and the Immune System

Manipulating the Tumor Environment

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

Adaptive (acquired) immunity. Professor Peter Delves University College London

The Adaptive Immune Responses

CD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells

Bases for Immunotherapy in Multiple Myeloma

FcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

Immunotherapy of HNC: immune mechanisms and therapeutic targets

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

The isbtc/sitc primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. Balwit et al.

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

REPROGRAMING IMMUNITY IN RENAL CELL CARCINOMA

Tim-3 as a target for tumor immunotherapy

Melanoma gene expression profiles to identify mechanisms of tumor resistance

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Novel strategies for enhancing the efficacy of therapeutic immunization against cancer Draghiciu, Oana

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Dra. Omayra Reyes, MD. Hematologist- Oncologist. Introduction to Immuno Oncology

Adaptive immune responses: T cell-mediated immunity

CANCER IMMUNOTHERAPY TARGETING T CELL COSTIMULATORY MOLECULES. Angela D. Pardee. B.A., Boston University, Submitted to the Graduate Faculty of

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1)

T cell and Cell-mediated immunity

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.

Advances in Cancer Immunotherapy

Immunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,

Basic mechanisms of Immunotherapy

Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors

Identification of novel immune regulators of tumor growth using highthroughput

Cancer immunity and immunotherapy. General principles

T cell-mediated immunity

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Title: Harnessing the immune system in acute myeloid leukaemia. Author: Rebecca Austin Mark J. Smyth Steven W. Lane

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Immunotherapy: The Newest Treatment Route

Biologic Basis of Immunotherapy in Lung Cancer

Combining ADCs with Immuno-Oncology Agents

Exploring the PD-L1 Pathway

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Radiation Therapy as an Immunomodulator

Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

Glioblastoma and CNS tumors

IMMUNOTARGET THERAPY: ASPETTI GENERALI

Synergistic combinations of targeted immunotherapy to combat cancer

T Cell Activation, Costimulation and Regulation

Glioma cancer stem cells mediate immune suppression that can be reversed with STAT3 blockade

Engineering chimeric antigen receptor-t cells for cancer treatment

Taking the brakes off the immune system: modelling effects in non-clinical safety studies

Immunotherapy in lung cancer. Saurabh maji

LESSON 2: THE ADAPTIVE IMMUNITY

Objectives. Abbas Chapter 11: Immunological Tolerance. Question 1. Question 2. Question 3. Definitions

T cell and Cell-mediated immunity

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

Hematopoiesis. Hematopoiesis. Hematopoiesis

Metabolic and functional reprogramming of myeloidderived suppressor cells and their therapeutic control in glioblastoma

Immune Regulation and Tolerance

Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Immune response. This overview figure summarizes simply how our body responds to foreign molecules that enter to it.

Respuesta inmune anti-tumoral. Aura Muntasell Institut Hospital del Mar d Investigacions Mèdiques Parc de Recerca Biomèdica de Barcelona

DNA vaccine, peripheral T-cell tolerance modulation 185

Immunology CANCER IMMUNOLOGY

Immune response to infection

Tumor Immunology: A Primer

Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways

TCR, MHC and coreceptors

Mesenchymal Stem Cells: Immunology and Therapeutic Benefits

Immune responses in autoimmune diseases

The development of T cells in the thymus

T Cell Effector Mechanisms I: B cell Help & DTH

T Cell Receptor & T Cell Development

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Glioblastoma and CNS tumors

Examples of questions for Cellular Immunology/Cellular Biology and Immunology

Transcription:

Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute

Hallmarks of Cancer: The Next Generation Role of the Immune System Immune Suppression in the TME Douglas Hanahan, Robert A. Weinberg, Cell, 2011, 244: 646-674

The Cancer-Immunity Cycle and Tumor Microenvironment (TME) Tumor Microenvironment Daniel S. Chen and Ira Mellman, Immunity, 2013, 39, 2013: 1-10

Cellular Infiltrates Within the TME Stromal Cells Tumorassociated Fibroblasts Endothelial Cells Pericytes Effector T cells Cytotoxic T cells: CTL CD4+ T cells Others Granulocytes Eosinophils Mast cells Platelets Kerkar S P, and Restifo N P Cancer Res 2012;72:3125-3130

Immunoregulatory Pathways Inhibit antigen-specific T Cell Function during Chronic antigen exposure Tim- 3 CTL IDO, arginase Suppressive/Regulatory Cells

Regulatory T cells: Tregs Natural and Induced Tregs (tumor antigen-specific Tregs) Can produce IL-10 and TGF-β Markers: Transcription factor forkhead box Foxp3, CTLA-4, GITR, CD39, Tim-3, VEGFR Suppress T and NK functions through multiple mechanisms (IL-2 deprivation, IL-10 and TGF-b secretion, granzyme-dependent cytolysis, adenosine production, DC crosstalk). Targeting Tregs: anti-cd25, anti-ctla-4 (ADCC), anti-gitr, TKis

Myelosuppressive Dendritic Cells: MDSCs Immature dendritic cells Lin-, HLA-DR-, CD33+ cells? Suppress T cell though cell-to-cell contact Produce NO ( nitration and nitrolysation of aa) and arginase 1 ( arginine depletion) IL-10 and reactive oxygen species production Favor Treg differentiation

Tumor cells and Immune Escape Loss of peptide-mhc complexe expression with downregulation of antigen processing machinery Express surface molecules that can kill CTLs: FasL, Trail Secrete immunosuppressive cytokines/molecules promoting T cell dysfunction:il-10, TGF-β, IDO, TDO, adenosine, PGE2, galectin 3 Hypoxia and tumor lactic acidosis can suppress CTLs They can upregulate inhibitory receptor ligands including PD-L1, HVEM, galectin 9 and HLA-DR. MHC class I+ MHC-Class I- Breast Cancer

Other Tumor-infiltrating Cells Tumor-Associated Macrophages Secrete immunosuppressive factors Recruit Tregs via CCL2 Produce Arginase 1 and inos Mast cells recruit MDCS and Tregs Cancer-Associated Fibroblasts recruit MDSCS Produce TGF-β Abnormal tumor vasculature with absence of high endothelial veinules limit mass transit of CTLs and represent an active barrier to tumor-reactive T cells May express FasL, Trail, PD-L1, IL-10, TGF-β. Maintained by tumor cells through paracrine mechanisms Targeting tumor microvasculature: VEGF blockade

Immunoregulatory Pathways Inhibit T Cell survival and function in the TME Tim- 3 CTL IDO, TDO Suppressive/Regulatory Cells

Immunosuppressive Effects of IDO in the TME

Immunoregulatory Pathways Inhibit antigen-specific T Cell Function during Chronic antigen exposure Tim- 3 CTL IDO, TDO Suppressive/Regulatory Cells

PD-1/B7-H1 (PD-L1) pathway

T Cell Dysfunction/Exhaustion Upon Chronic Antigen Exposure

T Cell Targets for Immunoregulatory Antibody Therapy I Mellman et al. Nature 480, 480-489 (2011)

Multiple co-stimulatory and inhibitory interactions regulate T cell responses.

Stimulatory and Inhibitory Factors in the Cancer-Immunity Cycle and Tumor Microenvironment Cytotoxic T cell (CTL) Cell Death or CTL Dysfunction

Manipulating the TME with Potent Immunotherapies of Cancer Daniel S. Chen and Ira Mellman, Immunity, 2013, 39, 2013: 1-10

Manipulating the TME with Therapeutic Targeting of the Hallmarks of Cancer Immunotherapy

Question 1 What receptor in the list below is not an inhibitory receptor expressed by T cells in the TME? PD-1? BTL-A Tim-3 LAG-3 CD28

Question 2 Please indicate the wrong answer: Dysfunctional/exhausted CTLs in the TME Upregulate PD-1 expression Loose their capacity to produce cytokines Loose their capacity to proliferate Occur in the TME upon chronic antigen stimulation Can potently lyse tumor cells

Question 3 Please indicate the wrong answer: Tregs in the TME Express Foxp3 Upregulate CD39 Suppress T cell functions Do not express CTLA-4

Question 4 Please indicate the wrong answer below Tumor cells in the TME may escape T cell destruction by the following mechanisms: Loss peptide-mhc complex expression with downregulation of antigen processing machinery PD-L1 expression Production of IL-10, TGF-β and galectin 3 Expressing MHC class I molecules